PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-3334

  1. 3,791 Posts.
    lightbulb Created with Sketch. 1554
    One of the reasons I was banging on with the capital raise was because I thought I was going to get diluted unnecessarily. In the end I just sucked it up and bought on market and I’d say that was one of the reasons for the low take up by retail shareholders. No need to buy in the cap raise when the institutions were dropping their golden tickets on the market.

    The last time I did the figures on this, my assumptions were that we’d eventually end up with 320m shares and maturity will start to unfold in 2032. I doubt it would be earlier and more likely a small delay.

    Since I’ve put my neck on the line for $355 sp, I think I’ll leave others to think about dividends with minimal overheads and income of $2 and a bit billion.

    TBH, I doubt we’ll get there without eventually fielding a takeover offer.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.